The Russian drug glyciphon, a representative of organophosphorus epoxides, for the treatment of basal cell carcinoma – clinical and experimental studies

The review deals with the results of clinical and experimental studies of the original Russian drug glyciphon used to treat basal cell carcinoma (BCC). Glyciphon is diglycidyl ether of methylphosphonic acid, which has been synthesized at the A. E. Arbuzov Institute of Organic and Physical Chemistry,...

Full description

Saved in:
Bibliographic Details
Main Authors: L. N. Zalyalyutdinova, R. S. Garaev
Format: Article
Language:Russian
Published: ABV-press 2015-11-01
Series:Опухоли головы и шеи
Subjects:
Online Access:https://ogsh.abvpress.ru/jour/article/view/169
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849401043805274112
author L. N. Zalyalyutdinova
R. S. Garaev
author_facet L. N. Zalyalyutdinova
R. S. Garaev
author_sort L. N. Zalyalyutdinova
collection DOAJ
description The review deals with the results of clinical and experimental studies of the original Russian drug glyciphon used to treat basal cell carcinoma (BCC). Glyciphon is diglycidyl ether of methylphosphonic acid, which has been synthesized at the A. E. Arbuzov Institute of Organic and Physical Chemistry, Kazan Research Center, Russian Academy of Sciences, belongs to a class of organophosphors epoxides. The drug has been experimentally tested by Kazan scientists who revealed the selectivity of its antiblastoma activity, relatively low toxicity, and high safety when it was used long. The antiproliferatve activity of glyciphon in inhibiting DNA synthesis, retarding all mitotic phases, and blocking the entry of cells into S and M phases plays an important role in its mechanism of antiblastoma action. Glyciphon ointment 30 % is effective in the treatment of primary BCC (solitary tumors and polyneoplasms) and its recurrences after radiation and surgery in the absence of a side skin resorption effect. It may be successfully used to treat BCC that are refractory to radiotherapy and surgical dissection and to detect latent foci of multiple BCC. The ointment is registered as an agent for the treatment of Stage I squamous cell carcinoma, as well as basaliomas (including recurrences after surgery and radiotherapy), Bowen,s disease, senile keratosis. Glyciphon is manufactured by OAO “Tatchempharmpreparaty” (Kazan) (as 30 % ointment from the substance made by the affiliate of the A. E. Arbuzov Institute of Organic and Physical Chemistry, Kazan Research Center, Russian Academy of Sciences.
format Article
id doaj-art-8ed291d4f9594cd7a851ee8cea5309d4
institution Kabale University
issn 2222-1468
2411-4634
language Russian
publishDate 2015-11-01
publisher ABV-press
record_format Article
series Опухоли головы и шеи
spelling doaj-art-8ed291d4f9594cd7a851ee8cea5309d42025-08-20T03:37:51ZrusABV-pressОпухоли головы и шеи2222-14682411-46342015-11-0153313810.17650/2222-1468-2015-5-3-31-38161The Russian drug glyciphon, a representative of organophosphorus epoxides, for the treatment of basal cell carcinoma – clinical and experimental studiesL. N. Zalyalyutdinova0R. S. Garaev1Kazan State Medical University, Ministry of Health of Russia; 49 Butlerov St., Kazan, 420012, RussiaKazan State Medical University, Ministry of Health of Russia; 49 Butlerov St., Kazan, 420012, RussiaThe review deals with the results of clinical and experimental studies of the original Russian drug glyciphon used to treat basal cell carcinoma (BCC). Glyciphon is diglycidyl ether of methylphosphonic acid, which has been synthesized at the A. E. Arbuzov Institute of Organic and Physical Chemistry, Kazan Research Center, Russian Academy of Sciences, belongs to a class of organophosphors epoxides. The drug has been experimentally tested by Kazan scientists who revealed the selectivity of its antiblastoma activity, relatively low toxicity, and high safety when it was used long. The antiproliferatve activity of glyciphon in inhibiting DNA synthesis, retarding all mitotic phases, and blocking the entry of cells into S and M phases plays an important role in its mechanism of antiblastoma action. Glyciphon ointment 30 % is effective in the treatment of primary BCC (solitary tumors and polyneoplasms) and its recurrences after radiation and surgery in the absence of a side skin resorption effect. It may be successfully used to treat BCC that are refractory to radiotherapy and surgical dissection and to detect latent foci of multiple BCC. The ointment is registered as an agent for the treatment of Stage I squamous cell carcinoma, as well as basaliomas (including recurrences after surgery and radiotherapy), Bowen,s disease, senile keratosis. Glyciphon is manufactured by OAO “Tatchempharmpreparaty” (Kazan) (as 30 % ointment from the substance made by the affiliate of the A. E. Arbuzov Institute of Organic and Physical Chemistry, Kazan Research Center, Russian Academy of Sciences.https://ogsh.abvpress.ru/jour/article/view/169glyciphonglyciphon ointment 30 %basal cell carcinomasquamous cell carcinoma polyneoplasmsrecurrent tumorsantiblastoma actionradiotherapysurgical treatmentorganophosphorus epoxides
spellingShingle L. N. Zalyalyutdinova
R. S. Garaev
The Russian drug glyciphon, a representative of organophosphorus epoxides, for the treatment of basal cell carcinoma – clinical and experimental studies
Опухоли головы и шеи
glyciphon
glyciphon ointment 30 %
basal cell carcinoma
squamous cell carcinoma polyneoplasms
recurrent tumors
antiblastoma action
radiotherapy
surgical treatment
organophosphorus epoxides
title The Russian drug glyciphon, a representative of organophosphorus epoxides, for the treatment of basal cell carcinoma – clinical and experimental studies
title_full The Russian drug glyciphon, a representative of organophosphorus epoxides, for the treatment of basal cell carcinoma – clinical and experimental studies
title_fullStr The Russian drug glyciphon, a representative of organophosphorus epoxides, for the treatment of basal cell carcinoma – clinical and experimental studies
title_full_unstemmed The Russian drug glyciphon, a representative of organophosphorus epoxides, for the treatment of basal cell carcinoma – clinical and experimental studies
title_short The Russian drug glyciphon, a representative of organophosphorus epoxides, for the treatment of basal cell carcinoma – clinical and experimental studies
title_sort russian drug glyciphon a representative of organophosphorus epoxides for the treatment of basal cell carcinoma clinical and experimental studies
topic glyciphon
glyciphon ointment 30 %
basal cell carcinoma
squamous cell carcinoma polyneoplasms
recurrent tumors
antiblastoma action
radiotherapy
surgical treatment
organophosphorus epoxides
url https://ogsh.abvpress.ru/jour/article/view/169
work_keys_str_mv AT lnzalyalyutdinova therussiandrugglyciphonarepresentativeoforganophosphorusepoxidesforthetreatmentofbasalcellcarcinomaclinicalandexperimentalstudies
AT rsgaraev therussiandrugglyciphonarepresentativeoforganophosphorusepoxidesforthetreatmentofbasalcellcarcinomaclinicalandexperimentalstudies
AT lnzalyalyutdinova russiandrugglyciphonarepresentativeoforganophosphorusepoxidesforthetreatmentofbasalcellcarcinomaclinicalandexperimentalstudies
AT rsgaraev russiandrugglyciphonarepresentativeoforganophosphorusepoxidesforthetreatmentofbasalcellcarcinomaclinicalandexperimentalstudies